Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

2
21
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 29 publications
(23 citation statements)
references
References 53 publications
2
21
0
Order By: Relevance
“…The median CD4 increase was of !161 cells/ mm 3 . 30 Overall, our results in treatment-naive individuals are in agreement with major findings in these two studies. Most of our patients (16 of 18; 88.9%) achieved viral suppression with a median CD4 gain at 1 year of !81 cells/mm 3 .…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…The median CD4 increase was of !161 cells/ mm 3 . 30 Overall, our results in treatment-naive individuals are in agreement with major findings in these two studies. Most of our patients (16 of 18; 88.9%) achieved viral suppression with a median CD4 gain at 1 year of !81 cells/mm 3 .…”
Section: Discussionsupporting
confidence: 91%
“…However, only 40% of participants were considered to have had a successful response to the predefined primary endpoint, which was a CD4 gain .100 cells/mm 3 . In the second study, conducted by the University of Washington-Dakar HIV-2 study group, 30 a total of 30 HIV-2 participants initiated elvitegravir/cobicistat/emtricitabine and tenofovir. Overall, 93.3% of individuals had viral suppression at week 48.…”
Section: Discussionmentioning
confidence: 99%
“…Data from case studies and small case series indicate that raltegravir-and elvitegravir-based regimens can suppress HIV-2 viral loads in ART-naive individuals (32,33) and in ART-experienced patients whose treatment history does not include an INI (32,(34)(35)(36)(37)(38)(39). More recently, two groups conducting clinical trials in ART-naive HIV-2-infected patients reported favorable immunovirologic outcomes in response to INI-based regimens (40,41). In addition, some evidence suggests that dolutegravir might be effective in a subset of HIV-2-infected patients who have developed resistance to raltegravir (42)(43)(44).…”
mentioning
confidence: 99%
“…Since 2018, WHO guidelines recommend tenofovir plus lamivudine plus dolutegravir based regimen as the preferred first-line option according to expert opinion, pilot studies and in vitro data [39]. This will change the management of HIV-2-infected patients with the use of boosted-PI such as lopinavir or darunavir with an optimized NRTI-backbone in second-line [21,27,[39][40][41]…”
Section: Discussionmentioning
confidence: 99%